Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Chunxia Su

Showing results (181-190 of 223) with videos related to

Pageof 23
Sort By:
Journal of Hematology & Oncology|July 14, 2019
Genomic landscape and its correlations with tumor mutational burden, PD-L1 expression, and immune cells infiltration in Chinese lung squamous cell carcinomaTao Jiang, Jinpeng Shi, Zhengwei Dong, et al.
Translational Lung Cancer Research|December 13, 2024
Construction of a risk prediction model for isolated pulmonary nodules 5-15 mm in diameterSiting Xie, Xingguang Luo, Yuxin Guo, et al.
Lung Cancer (Amsterdam, Netherlands)|December 17, 2013
MiR-21 overexpression is associated with acquired resistance of EGFR-TKI in non-small cell lung cancerBing Li, Shengxiang Ren, Xuefei Li, et al.
Journal of Cellular and Molecular Medicine|January 3, 2020
Exosomes transmit T790M mutation-induced resistance in EGFR-mutant NSCLC by activating PI3K/AKT signalling pathwayXiaozhen Liu, Tao Jiang, Xuefei Li, et al.
Signal Transduction and Targeted Therapy|May 22, 2025
Harnessing local and system immune profiling delineating differential responders to first-line sintilimab (anti-PD-1 antibody) combined with chemotherapy in extensive-stage small cell lung cancer: an exploratory biomarker analysis of a phase II studyMengqing Xie, Minwei Bao, Xiaorong Dong, et al.
Lung Cancer (Amsterdam, Netherlands)|March 15, 2016
Feasibility of cytological specimens for ALK fusion detection in patients with advanced NSCLC using the method of RT-PCRYan Wang, Yu Liu, Chao Zhao, et al.
Oncology Letters|November 23, 2017
Characterization of distinct types of <i>KRAS</i> mutation and its impact on first-line platinum-based chemotherapy in Chinese patients with advanced non-small cell lung cancerYijun Jia, Tao Jiang, Xuefei Li, et al.
International Journal of Cancer|June 14, 2025
Optimizing management of stage IV EGFR mutant non-small cell lung cancer in Asia: An expert opinionGee-Chen Chang, Akhil Kapoor, Chee Khoon Lee, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|September 10, 2015
EML4-ALK Fusion Detected by RT-PCR Confers Similar Response to Crizotinib as Detected by FISH in Patients with Advanced Non-Small-Cell Lung CancerYan Wang, Jun Zhang, Guanghui Gao, et al.
Nature Communications|June 12, 2026
Cadonilimab plus chemotherapy as first-line treatment in PD-L1-negative advanced non-small cell lung cancer: a phase II clinical trialLi Wang, Chuangzhou Rao, Qi Wang, et al.
Pageof 23

Showing results (181-190 of 223) with videos related to

Sort By:
Pageof 23
Journal of Hematology & Oncology|July 14, 2019
Genomic landscape and its correlations with tumor mutational burden, PD-L1 expression, and immune cells infiltration in Chinese lung squamous cell carcinomaTao Jiang, Jinpeng Shi, Zhengwei Dong, et al.
Translational Lung Cancer Research|December 13, 2024
Construction of a risk prediction model for isolated pulmonary nodules 5-15 mm in diameterSiting Xie, Xingguang Luo, Yuxin Guo, et al.
Lung Cancer (Amsterdam, Netherlands)|December 17, 2013
MiR-21 overexpression is associated with acquired resistance of EGFR-TKI in non-small cell lung cancerBing Li, Shengxiang Ren, Xuefei Li, et al.
Journal of Cellular and Molecular Medicine|January 3, 2020
Exosomes transmit T790M mutation-induced resistance in EGFR-mutant NSCLC by activating PI3K/AKT signalling pathwayXiaozhen Liu, Tao Jiang, Xuefei Li, et al.
Signal Transduction and Targeted Therapy|May 22, 2025
Harnessing local and system immune profiling delineating differential responders to first-line sintilimab (anti-PD-1 antibody) combined with chemotherapy in extensive-stage small cell lung cancer: an exploratory biomarker analysis of a phase II studyMengqing Xie, Minwei Bao, Xiaorong Dong, et al.
Lung Cancer (Amsterdam, Netherlands)|March 15, 2016
Feasibility of cytological specimens for ALK fusion detection in patients with advanced NSCLC using the method of RT-PCRYan Wang, Yu Liu, Chao Zhao, et al.
Oncology Letters|November 23, 2017
Characterization of distinct types of <i>KRAS</i> mutation and its impact on first-line platinum-based chemotherapy in Chinese patients with advanced non-small cell lung cancerYijun Jia, Tao Jiang, Xuefei Li, et al.
International Journal of Cancer|June 14, 2025
Optimizing management of stage IV EGFR mutant non-small cell lung cancer in Asia: An expert opinionGee-Chen Chang, Akhil Kapoor, Chee Khoon Lee, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|September 10, 2015
EML4-ALK Fusion Detected by RT-PCR Confers Similar Response to Crizotinib as Detected by FISH in Patients with Advanced Non-Small-Cell Lung CancerYan Wang, Jun Zhang, Guanghui Gao, et al.
Nature Communications|June 12, 2026
Cadonilimab plus chemotherapy as first-line treatment in PD-L1-negative advanced non-small cell lung cancer: a phase II clinical trialLi Wang, Chuangzhou Rao, Qi Wang, et al.
Pageof 23